UroGen Pharma Analyst Ratings
UroGen Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/31/2023 | -20.39% | Goldman Sachs | $11 → $18 | Maintains | Neutral |
| 06/21/2023 | 1.72% | HC Wainwright & Co. | → $23 | Reiterates | Buy → Buy |
| 05/15/2023 | -2.7% | Oppenheimer | → $22 | Reiterates | Outperform → Outperform |
| 05/15/2023 | 1.72% | HC Wainwright & Co. | → $23 | Reiterates | Buy → Buy |
| 05/02/2023 | 1.72% | HC Wainwright & Co. | → $23 | Reiterates | → Buy |
| 04/10/2023 | 1.72% | HC Wainwright & Co. | → $23 | Reiterates | → Buy |
| 02/16/2023 | 1.72% | HC Wainwright & Co. | → $23 | Reiterates | → Buy |
| 02/08/2023 | -55.77% | Jefferies | $35 → $10 | Downgrades | Buy → Hold |
| 12/12/2022 | 1.72% | HC Wainwright & Co. | $26 → $23 | Maintains | Buy |
| 04/27/2022 | -11.54% | Berenberg | → $20 | Initiates Coverage On | → Buy |
| 03/22/2022 | -51.35% | Goldman Sachs | $10 → $11 | Maintains | Neutral |
| 01/18/2022 | 50.38% | HC Wainwright & Co. | $50 → $34 | Maintains | Buy |
| 04/27/2021 | 121.14% | HC Wainwright & Co. | $57 → $50 | Maintains | Buy |
| 04/17/2020 | 107.87% | Oppenheimer | $45 → $47 | Maintains | Outperform |
| 04/16/2020 | 152.1% | HC Wainwright & Co. | $53 → $57 | Reiterates | → Buy |
| 04/13/2020 | 134.41% | HC Wainwright & Co. | $75 → $53 | Maintains | Buy |
| 04/06/2020 | 99.03% | Oppenheimer | $47 → $45 | Maintains | Outperform |
| 01/13/2020 | 129.99% | Oppenheimer | $62 → $52 | Maintains | Outperform |
| 11/13/2019 | 72.49% | JP Morgan | $40 → $39 | Maintains | Neutral |
| 05/30/2019 | 81.34% | JP Morgan | → $41 | Initiates Coverage On | → Neutral |
| 05/29/2019 | 121.14% | Goldman Sachs | → $50 | Initiates Coverage On | → Neutral |
| 01/29/2019 | 262.67% | HC Wainwright & Co. | → $82 | Initiates Coverage On | → Buy |
| 11/08/2018 | 240.56% | Jefferies | → $77 | Assumes | → Buy |
| 09/14/2018 | 209.6% | Stifel | → $70 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 07/31/2023 | -20.39% | 高盛 | 11 美元 → 18 美元 | 维护 | 中立 |
| 06/21/2023 | 1.72% | HC Wainwright & Co. | → 23 美元 | 重申 | 购买 → 购买 |
| 05/15/2023 | -2.7% | 奥本海默 | → 22 美元 | 重申 | 跑赢大盘 → 跑赢大盘 |
| 05/15/2023 | 1.72% | HC Wainwright & Co. | → 23 美元 | 重申 | 购买 → 购买 |
| 05/02/2023 | 1.72% | HC Wainwright & Co. | → 23 美元 | 重申 | → 购买 |
| 2023 年 10 月 4 日 | 1.72% | HC Wainwright & Co. | → 23 美元 | 重申 | → 购买 |
| 02/16/2023 | 1.72% | HC Wainwright & Co. | → 23 美元 | 重申 | → 购买 |
| 02/08/2023 | -55.77% | 杰富瑞 | 35 美元 → 10 美元 | 降级 | 买入 → 持有 |
| 2022 年 12 月 12 日 | 1.72% | HC Wainwright & Co. | 26 美元 → 23 美元 | 维护 | 购买 |
| 04/27/2022 | -11.54% | 贝伦贝格 | → 20 美元 | 启动覆盖开启 | → 购买 |
| 03/22/2022 | -51.35% | 高盛 | 10 美元 → 11 美元 | 维护 | 中立 |
| 01/18/2022 | 50.38% | HC Wainwright & Co. | 50 美元 → 34 美元 | 维护 | 购买 |
| 04/27/2021 | 121.14% | HC Wainwright & Co. | 57 美元 → 50 美元 | 维护 | 购买 |
| 2020 年 4 月 17 日 | 107.87% | 奥本海默 | 45 美元 → 47 美元 | 维护 | 跑赢大盘 |
| 2020 年 4 月 16 日 | 152.1% | HC Wainwright & Co. | 53 美元 → 57 美元 | 重申 | → 购买 |
| 2020 年 4 月 13 日 | 134.41% | HC Wainwright & Co. | 75 美元 → 53 美元 | 维护 | 购买 |
| 2020 年 6 月 4 日 | 99.03% | 奥本海默 | 47 美元 → 45 美元 | 维护 | 跑赢大盘 |
| 2020 年 1 月 13 日 | 129.99% | 奥本海默 | 62 美元 → 52 美元 | 维护 | 跑赢大盘 |
| 11/13/2019 | 72.49% | 摩根大通 | 40 美元 → 39 美元 | 维护 | 中立 |
| 2019 年 5 月 30 日 | 81.34% | 摩根大通 | → 41 美元 | 启动覆盖开启 | → 中立 |
| 05/29/2019 | 121.14% | 高盛 | → 50 美元 | 启动覆盖开启 | → 中立 |
| 2019 年 1 月 29 日 | 262.67% | HC Wainwright & Co. | → 82 美元 | 启动覆盖开启 | → 购买 |
| 11/08/2018 | 240.56% | 杰富瑞 | → 77 美元 | 假设 | → 购买 |
| 09/14/2018 | 209.6% | Stifel | → 70 美元 | 启动覆盖开启 | → 购买 |
What is the target price for UroGen Pharma (URGN)?
UroGen Pharma（URGN）的目标价格是多少？
The latest price target for UroGen Pharma (NASDAQ: URGN) was reported by Goldman Sachs on July 31, 2023. The analyst firm set a price target for $18.00 expecting URGN to fall to within 12 months (a possible -20.39% downside). 9 analyst firms have reported ratings in the last year.
高盛于2023年7月31日公布了UroGen Pharma（纳斯达克股票代码：URGN）的最新目标股价。这家分析公司将目标股价定为18.00美元，预计URGN将在12个月内跌至-20.39％（可能下跌-20.39％）。去年有9家分析公司公布了评级。
What is the most recent analyst rating for UroGen Pharma (URGN)?
分析师对UroGen Pharma（URGN）的最新评级是多少？
The latest analyst rating for UroGen Pharma (NASDAQ: URGN) was provided by Goldman Sachs, and UroGen Pharma maintained their neutral rating.
UroGen Pharma（纳斯达克股票代码：URGN）的最新分析师评级由高盛提供，UroGen Pharma维持中性评级。
When is the next analyst rating going to be posted or updated for UroGen Pharma (URGN)?
UroGen Pharma（URGN）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of UroGen Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for UroGen Pharma was filed on July 31, 2023 so you should expect the next rating to be made available sometime around July 31, 2024.
分析师在进行了广泛的研究（包括浏览公开财务报表、与UroGen Pharma的高管和客户交谈以及听取财报电话会议）后得出了股票评级。大多数分析师每三个月进行一次评级，因此每家公司每年应该获得4个评级。UroGen Pharma的最后一次评级是在2023年7月31日提交的，因此您应该预计下一个评级将在2024年7月31日左右公布。
Is the Analyst Rating UroGen Pharma (URGN) correct?
分析师对 UroGen Pharma (URGN) 的评级正确吗？
While ratings are subjective and will change, the latest UroGen Pharma (URGN) rating was a maintained with a price target of $11.00 to $18.00. The current price UroGen Pharma (URGN) is trading at is $22.61, which is out of the analyst's predicted range.
尽管评级是主观的，将会发生变化，但最新的UroGen Pharma（URGN）评级维持不变，目标股价为11.00美元至18.00美元。UroGen Pharma（URGN）目前的交易价格为22.61美元，超出了分析师的预测区间。